At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 29 enrolled
Drug / intervention
Netarsudil Ophthalmic Solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Randomized Study to Determine Whether Use of Rhopressa™ Can Ameliorate Corneal Edema Associated With Fuchs Dystrophy
In Brief
A Phase 3 clinical trial evaluating Netarsudil Ophthalmic Solution and Placebo for Fuchs Endothelial Dystrophy. Completed, enrolled 29 participants across 1 site.
Detailed Summary
The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a corneal transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFuchs Endothelial Dystrophy
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartAug 2019
First PostedAug 2019
Primary CompletionJul 2020
TodayJul 2026
First PostedAug 9, 2019
Enrollment StartAug 5, 2019
Primary CompletionJul 1, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.9 years ago
Interventions
Netarsudil Ophthalmic Solutiondrug
Netarsudil eye drops instilled once daily
Placebodrug
Placebo eye drops instilled once daily